Appl. No.

08/765,837

Filed

September 7, 1999

a human Factor VIII fragment contained between arginine 1652 and tyrosine 1664 (SEQ ID No:1), a human Factor VIII fragment contained between threonine 1739 and tyrosine 1748 (SEQ ID No:3), a human Factor VIII fragment contained between asparagine 1777 and phenylalanine 1785 (SEQ ID No:4), a human Factor VIII fragment contained between glutamic acid 1794 and tyrosine 1815 (SEQ ID No:5), a human Factor VIII fragment contained between methionine 1823 and aspartic acid 1831 (SEQ ID No:6), a human Factor VIII fragment contained between glutamic acid 1885 and phenylalanine 1891 (SEQ ID No:7), a human Factor VIII fragment contained between glutamic acid 1893 and alanine 1901 (SEQ ID No:8), and a human Factor VIII fragment contained between aspartic acid 1909 and arginine 1917 (SEQ ID No:9).

- 33. **(Twice Amended)** The antigenic polypeptide according to Claim 31, wherein said antigenic polypeptide comprises tyrosine or histidine.
- 34. (Twice Amended) A conformational epitope containing at least two different human Factor VIII fragments of Claim 32, wherein said fragments are positioned in proximity to each other when the protein is folded in its tertiary or quaternary structure to form a conformational epitope which is recognized by an inhibitor of Factor VIII selected from the group consisting of B lymphocytes, MHC I proteins, MHC II proteins, and anti-Factor VIII antibodies.
- 35. (Twice Amended) A conformational epitope containing at least two different epitopes from a human Factor VIII fragment selected from the group consisting of a human Factor VIII fragment contained between arginine 1652 and arginine 1696 inclusive, a human Factor VIII fragment contained between threonine 1739 and aspartic acid 1831, inclusive, and a human Factor VIII fragment contained between glutamic acid 1885 and arginine 1917 inclusive.
- 36. (Twice Amended) A complex comprising a carrier protein or a carrier peptide linked to the antigenic polypeptide of Claim 31 or the conformational epitope of Claim 35, whereby said complex increases immunogenicity.